The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Open accessAbstract
Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma (HCC) since 2007 and numerous studies have investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Hu, B., Yang, X.-R., Xu, Y., Sun, Y.-F., Sun, C., Guo, W., Zhang, X., Wang, W.-M., Qiu, S.-J., Zhou, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0442 · Cited by 2,493
Cited by
Biology and significance of alpha-fetoprotein in hepatocellular carcinoma
Galle, P. R., Foerster, F., Kudo, M., Chan, S. L., Llovet, J. M., Qin, S., Schelman, W. R., Chintharlapalli, S., Abada, P. B., Sherman, M., et al. (2019) · Liver International · doi:10.1111/liv.14223 · Cited by 597
Qin, S., Bi, F., Gu, S., Bai, Y., Chen, Z., Wang, Z., Ying, J., Lu, Y., Meng, Z., Pan, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00163 · Cited by 409
Metadata
- Authors
- Marisi, G., Cucchetti, A., Ulivi, P., Canale, M., Cabibbo, G., Solaini, L., Foschi, F. G., Matteis, S. D., Ercolani, G., Valgiusti, M., Frassineti, G. L., Scartozzi, M., & Gardini, A. C.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2018-09-28
- Volume
- 24
- Issue
- 36
- Pages
- 4152-4163
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W2893868814
- Cited by
- 184
- References
- 2
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.